Thermo Fisher Scientific Adds Aseptic Capacity
The Pharma Services business of Thermo Fisher Scientific will invest $150 Million at three facilities.
Thermo Fisher Scientific Inc. will invest $150 million at three Pharma Services business sites in Monza and Ferentino, Italy, and Greenville, NC to add capacity for sterile liquid and lyophilized product development and commercial manufacturing.
Each site will be equipped with aseptic filling lines and isolator technology. Construction is expected to be completed within the next 24 months, the company reported in a March 18, 2019 press statement announcing the investment.
"These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise," said Michel Lagarde, president of pharma services for Thermo Fisher Scientific. "We continue to invest to expand our capabilities and help our customers deliver the highest quality medicines to the patients who need them."
Source: Thermo Fisher Scientific
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
